Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 3/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10757678 | 0.87 | TP53 (0.51) | MLYCDSMN1; SMN2MEN1KMT2ACYP3A4 | |
| SCHEMBL15957135 | 0.84 | NPC1 (0.52) | MLYCDSMN1; SMN2MEN1KMT2ACYP3A4 | |
| SCHEMBL10951512 | 0.83 | ALDH1A1 (0.61) | MLYCDSMN1; SMN2MEN1KMT2ACYP3A4 | |
| SCHEMBL6047685 | 0.81 | MLYCD (0.48) | MLYCDALDH1A1GLATSHR | |
| SCHEMBL14690329 | 0.81 | MLYCD (0.48) | MLYCDALDH1A1GLATSHR | |
| SCHEMBL9330080 | 0.79 | ALDH1A1 (0.43) | SMN1; SMN2MEN1KMT2ACYP3A4CYP2C9 | |
| SCHEMBL9330076 | 0.79 | ALDH1A1 (0.43) | SMN1; SMN2MEN1KMT2ACYP3A4CYP2C9 | |
| SCHEMBL10333122 | 0.79 | ALDH1A1 (0.43) | SMN1; SMN2MEN1KMT2ACYP3A4CYP2C9 | |
| SCHEMBL10814884 | 0.79 | ADRA2C (0.43) | MLYCDSMN1; SMN2MEN1KMT2ACYP3A4 | |
| SCHEMBL9662182 | 0.79 | ALDH1A1 (0.43) | SMN1; SMN2MEN1KMT2ACYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7803785-B2 | Gemcitabine prodrugs, pharmaceutical compositions and uses thereof | XENOPORT, INC. (US) | 2010-09-28 | — | — | US | disclosed |
| US-20100016254-A1 | GEMCITABINE PRODRUGS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2010-01-21 | — | — | US | disclosed |
| US-7608602-B2 | Gemcitabine prodrugs, pharmaceutical compositions and uses thereof | XENOPORT, INC. (US) | 2009-10-27 | — | — | US | disclosed |
| US-20080021208-A1 | Gemcitabine Prodrugs, Pharmaceutical Compositions and Uses Thereof | XENOPORT, INC. (US) | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016254-A1 | GEMCITABINE PRODRUGS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | TYMP, GDA, GCG | MLYCD 2583/4885SMN1; SMN2 1468/4885MEN1 1273/4885 |
| US-20080021208-A1 | Gemcitabine Prodrugs, Pharmaceutical Compositions and Uses Thereof | TYMP, GDA, GCG | MLYCD 2583/4885SMN1; SMN2 1468/4885MEN1 1273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.